Abingworth

Abingworth is a premier transatlantic life sciences investment firm dedicated to converting pioneering science into innovative medicines. Through strategic capital and expert guidance, Abingworth empowers exceptional management teams in building world-class companies.

With a rich history dating back to 1973, Abingworth has invested in over 180 life science ventures, resulting in 46 mergers and acquisitions, and over 70 initial public offerings. Our investment approach focuses on three key areas: seed and early-stage ventures, development-stage companies, and clinical co-development initiatives. Abingworth has offices at 38 Jermyn Street, London, UK, SW1Y 6DN, GB; 3000 Sand Hill Road, B4-135, Menlo Park, CA CA 94025, US; and 420 Boylston Street, Suite 405, Boston, MA 02116, US.

Abingworth supports its portfolio companies with a team of seasoned professionals. Abingworth became part of Carlyle (NASDAQ: CG) on August 1, 2022. We invite the management team at Abingworth to further enrich our platform by creating a customized and exclusive company showcase and product listing.